Skip to main content
. 2021 Aug 23;9(8):1072. doi: 10.3390/biomedicines9081072
API active pharmaceutical ingredient
ATMP advanced therapy medicinal product
BCA bicinchoninic acid assay
BPyV bovine polyomavirus
BSA bovine serum albumin
CD cluster of differentiation
CHUV Centre hospitalier universitaire Vaudois
CPP critical process parameter
CQA critical quality attribute
DMEM Dulbecco’s modified Eagle medium
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
EBV Epstein-Barr virus
EC European Commission
ECACC European collection of authenticated cell cultures
EDQM European Directorate for the Quality of Medicines & Healthcare
EDTA ethylenediaminetetraacetic acid
ELISA enzyme-linked immunosorbent assay
EOPCB end of production cell bank
EP European Pharmacopoeia
ESC embryonic stem cells
FACS fluorescence activated cell-sorting
FBS fetal bovine serum
FDA US Food and Drug Administration
FPC fibroblast progenitor cells
FT freeze-thaw
GMP good manufacturing practices
HAV hepatitis A virus
HBV hepatitis B virus
HBoV human bocavirus
hCMV human cytomegalovirus
HCV hepatitis C virus
HHV human herpes virus
HIV human immunodeficiency virus
HPV human papilloma virus
HTLV human T-cell lymphotropic virus
IPC in-process control
KIPyV KI polyomavirus
KPP key process parameter
LYO lyophilizate
MCB master cell bank
MoA mechanism of action
MSC mesenchymal stem cells
PBB Progenitor Biological Bandage
PBS phosphate-buffered saline
PCB parental cell bank
PDT population doubling time
PDV population doubling value
PPC post-process control
RH relative humidity
SD standard deviation
SV40 simian virus 40
TEM transmission electron microscopy
TEP tissue engineering product
TrSt standardized transplant product
USA United States of America
WCB working cell bank
WUPyV WU polyomavirus